Halozyme Therapeutics annual ebitda
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Halozyme Therapeutics EBITDA Growth & History (HALO)
Halozyme Therapeutics's calculated EBITDA was $480.4M for fiscal 2025.
View full Halozyme Therapeutics company overviewHalozyme Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $480.4M | −$81.3M | −14.48% |
| 2024 | 2024-12-31 | $561.7M | $213.1M | +61.11% |
| 2023 | 2023-12-31 | $348.7M | $74.6M | +27.24% |
| 2022 | 2022-12-31 | $274.0M | −$4.9M | −1.75% |
| 2021 | 2021-12-31 | $278.9M | $131.4M | +89.03% |
| 2020 | 2020-12-31 | $147.5M | $211.1M | — |
| 2019 | 2019-12-31 | −$63.5M | $3.4M | — |
| 2018 | 2018-12-31 | −$66.9M | −$150.1M | — |
| 2017 | 2017-12-31 | $83.2M | $164.0M | — |
| 2016 | 2016-12-31 | −$80.8M | −$55.0M | — |
| 2015 | 2015-12-31 | −$25.8M | $35.5M | — |
| 2014 | 2014-12-31 | −$61.3M | $17.9M | — |
| 2013 | 2013-12-31 | −$79.2M | −$26.7M | — |
| 2012 | 2012-12-31 | −$52.5M | −$33.8M | — |
| 2011 | 2011-12-31 | −$18.7M | $34.0M | — |
| 2010 | 2010-12-31 | −$52.7M | $4.3M | — |
| 2009 | 2009-12-31 | −$57.0M | — | — |
Halozyme Therapeutics quarterly ebitda
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $292.2M | $87.0M | +42.42% |
| Q1 2026 | 2026-03-31 | $188.7M | $44.5M | +30.87% |
| Q4 2025 | 2025-12-31 | −$89.6M | −$267.7M | — |
| Q3 2025 | 2025-09-30 | $220.6M | $54.8M | +33.07% |
| Q2 2025 | 2025-06-30 | $205.1M | $85.3M | +71.19% |
| Q1 2025 | 2025-03-31 | $144.2M | $46.2M | +47.19% |
| Q4 2024 | 2024-12-31 | $178.1M | $74.1M | +71.28% |
| Q3 2024 | 2024-09-30 | $165.8M | $74.8M | +82.24% |
| Q2 2024 | 2024-06-30 | $119.8M | $22.6M | +23.21% |
| Q1 2024 | 2024-03-31 | $98.0M | $41.6M | +73.66% |
| Q4 2023 | 2023-12-31 | $104.0M | $26.9M | +34.84% |
| Q3 2023 | 2023-09-30 | $91.0M | $5.7M | +6.67% |
| Q2 2023 | 2023-06-30 | $97.3M | $62.1M | +176.62% |
| Q1 2023 | 2023-03-31 | $56.4M | −$20.0M | −26.19% |
| Q4 2022 | 2022-12-31 | $77.1M | $19.8M | +34.61% |
| Q3 2022 | 2022-09-30 | $85.3M | $9.0M | +11.81% |
| Q2 2022 | 2022-06-30 | $35.2M | −$58.7M | −62.53% |
| Q1 2022 | 2022-03-31 | $76.4M | $25.0M | +48.52% |
| Q4 2021 | 2021-12-31 | $57.3M | −$21.2M | −26.97% |
| Q3 2021 | 2021-09-30 | $76.3M | $35.2M | +85.62% |
| Q2 2021 | 2021-06-30 | $93.8M | $63.5M | +209.16% |
| Q1 2021 | 2021-03-31 | $51.5M | $53.8M | — |
| Q4 2020 | 2020-12-31 | $78.5M | $109.4M | — |
| Q3 2020 | 2020-09-30 | $41.1M | $64.6M | — |
| Q2 2020 | 2020-06-30 | $30.4M | $43.3M | — |
| Q1 2020 | 2020-03-31 | −$2.4M | −$6.3M | — |
| Q4 2019 | 2019-12-31 | −$31.0M | −$31.5M | — |
| Q3 2019 | 2019-09-30 | −$23.5M | $1.3M | — |
| Q2 2019 | 2019-06-30 | −$13.0M | $6.5M | — |
| Q1 2019 | 2019-03-31 | $4.0M | $27.1M | — |
| Q4 2018 | 2018-12-31 | $551,000 | −$125.8M | −99.56% |
| Q3 2018 | 2018-09-30 | −$24.9M | −$33.5M | — |
| Q2 2018 | 2018-06-30 | −$19.5M | $5.4M | — |
| Q1 2018 | 2018-03-31 | −$23.1M | $3.8M | — |
| Q4 2017 | 2017-12-31 | $126.4M | $148.3M | — |
| Q3 2017 | 2017-09-30 | $8.6M | $30.6M | — |
| Q2 2017 | 2017-06-30 | −$24.9M | −$3.8M | — |
| Q1 2017 | 2017-03-31 | −$26.9M | −$11.2M | — |
| Q4 2016 | 2016-12-31 | −$22.0M | −$27.9M | — |
| Q3 2016 | 2016-09-30 | −$22.0M | $794,000 | — |
| Q2 2016 | 2016-06-30 | −$21.1M | −$25.8M | — |
| Q1 2016 | 2016-03-31 | −$15.7M | −$2.2M | — |
| Q4 2015 | 2015-12-31 | $5.9M | $9.2M | — |
| Q3 2015 | 2015-09-30 | −$22.8M | −$4.2M | — |
| Q2 2015 | 2015-06-30 | $4.6M | $19.2M | — |
| Q1 2015 | 2015-03-31 | −$13.5M | $11.3M | — |
| Q4 2014 | 2014-12-31 | −$3.3M | $17.7M | — |
| Q3 2014 | 2014-09-30 | −$18.6M | −$432,000 | — |
| Q2 2014 | 2014-06-30 | −$14.5M | $7.3M | — |
| Q1 2014 | 2014-03-31 | −$24.8M | −$6.6M | — |
| Q4 2013 | 2013-12-31 | −$21.0M | −$16.9M | — |
| Q3 2013 | 2013-09-30 | −$18.2M | $1.5M | — |
| Q2 2013 | 2013-06-30 | −$21.8M | −$8.0M | — |
| Q1 2013 | 2013-03-31 | −$18.2M | −$3.3M | — |
| Q4 2012 | 2012-12-31 | −$4.1M | $14.1M | — |
| Q3 2012 | 2012-09-30 | −$19.7M | −$25.1M | — |
| Q2 2012 | 2012-06-30 | −$13.8M | −$17.2M | — |
| Q1 2012 | 2012-03-31 | −$14.9M | −$5.6M | — |
| Q4 2011 | 2011-12-31 | −$18.2M | — | — |
| Q3 2011 | 2011-09-30 | $5.4M | $17.5M | — |
| Q2 2011 | 2011-06-30 | $3.4M | — | — |
| Q1 2011 | 2011-03-31 | −$9.3M | — | — |
| Q3 2010 | 2010-09-30 | −$12.1M | — | — |
Halozyme Therapeutics ebitda trends
Over the last five fiscal years, Halozyme Therapeutics's ebitda increased from $147.5M to $480.4M, a change of $332.9M. The latest reported quarter, Q2 2026, shows $292.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Halozyme Therapeutics source filings ↗Community posts
Halozyme prices a larger $1.3 billion convertible financing
Halozyme ($HALO) increased its convertible-note offering to $1.3 billion from $1.05 billion and set a 1.50% coupon. The notes mature in 2033 and initially convert at approximately $139.84 per share, a 27.5% premium to the reference share pr ...
Halozyme proposes $1.05 billion convertible refinancing
Halozyme ($HALO) announced plans to sell $1.05 billion of convertible senior notes due in 2033, with an option for initial purchasers to buy a further $150 million. The securities would be senior unsecured obligations paying interest twice ...
